Tolterodine tartrate
The active substance in Tolzurin is tolterodine. Tolterodine belongs to a group of medicines called antimuscarinic agents.
Tolzurin is used to treat the symptoms of overactive bladder syndrome. When overactive bladder syndrome occurs, patients may experience:
Before starting to take Tolzurin, discuss with your doctor or pharmacist:
Tell your doctor about all the medicines you are taking now or have taken recently, as well as any medicines you plan to take.
Tolterodine, the active substance in Tolzurin, may interact with other medicines.
Do not take Tolzurin with:
Be cautious when taking Tolzurin with:
Tolzurin can be taken before, after, or during a meal.
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy
Do not take Tolzurin during pregnancy.
Breastfeeding
It is not known whether tolterodine, the active substance in Tolzurin, is excreted in breast milk. Do not take Tolzurin while breastfeeding.
Tolzurin may cause dizziness, tiredness, and affect vision, which may impair your ability to drive or operate machinery.
If you have been told that you have an intolerance to some sugars, contact your doctor before taking this medicine.
This medicine contains less than 1 mmol (23 mg) of sodium per dose, which is considered to be essentially sodium-free.
Always take this medicine exactly as your doctor has told you.
In case of doubt, consult your doctor or pharmacist.
Do not chew the capsules.
Adults
The recommended dose is one 4 mg prolonged-release hard capsule per day.
Patient with liver or kidney disease or troublesome side effects:
Your doctor may reduce the dose of Tolzurin to one 2 mg capsule per day.
Use in children
Tolzurin is not recommended for use in children.
If you have taken too many capsules, contact your doctor or pharmacist immediately.
If you miss a dose, take it as soon as you remember, unless it is almost time for your next dose. In this case, skip the missed dose and continue with your normal schedule.
Do not take a double dose to make up for a forgotten dose.
Your doctor will tell you how long to take Tolzurin.
Do not stop treatment early, as it may take time for your bladder to adapt.
Complete the treatment with the capsules as prescribed by your doctor.
Contact your doctor if you have not seen any effect after this time.
The effect of the treatment should be evaluated after 2-3 months.
Always consult your doctor if you are considering stopping treatment.
In case of any further doubts about the use of this medicine, consult your doctor or pharmacist.
Like all medicines, Tolzurin can cause side effects, although not everybody gets them.
Contact your doctor or go to the emergency room if you experience symptoms of an allergic reaction, such as:
This reaction occurs uncommonly (in less than 1 in 100 patients).
Contact your doctor or go to the emergency room if you experience:
During treatment with tolterodine, the following side effects have been observed with the following frequency:
Very common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Additional reported reactions include severe allergic reactions, confusion, hallucinations, rapid heartbeat, skin redness, heartburn, vomiting, severe swelling of the skin, especially around the mouth, eyes, genitals, hands, or feet (angioedema), dry skin, and disorientation.
There have also been reports of worsening symptoms of dementia in patients being treated for this condition.
If you experience any side effects, including those not listed in this package leaflet, inform your doctor or pharmacist.
Side effects can be reported directly to the Department of Drug Safety Monitoring of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the carton and blister after EXP.
The expiry date refers to the last day of the month.
Do not store above 25°C.
Medicines should not be disposed of via wastewater or household waste.
Ask your pharmacist how to dispose of medicines no longer required.
This will help protect the environment.
The active substance in Tolzurin, 2 mg, prolonged-release hard capsules is 2 mg of tolterodine tartrate, which corresponds to 1.37 mg of tolterodine.
The active substance in Tolzurin, 4 mg, prolonged-release hard capsules is 4 mg of tolterodine tartrate, which corresponds to 2.74 mg of tolterodine.
The other ingredients are:
Lactose monohydrate, microcrystalline cellulose, polyvinyl acetate, povidone, colloidal silicon dioxide, sodium lauryl sulfate, sodium docusate, magnesium stearate, hypromellose.
Capsule shell: indigo carmine (E 132), quinoline yellow (only in 2 mg capsules) (E 104), titanium dioxide (E 171), gelatin.
Inner tablet coating: ethylcellulose, triethyl citrate, methacrylic acid, and ethyl acrylate copolymer, dispersion 30%, propylene glycol.
Tolzurin is available in the form of prolonged-release hard capsules for once-daily oral administration.
Tolzurin, 2 mg, prolonged-release hard capsules are green, size 1, hard gelatin capsules containing two white, round, biconvex, film-coated tablets.
Tolzurin, 4 mg, prolonged-release hard capsules are light blue, size 1, hard gelatin capsules containing four white, round, biconvex, film-coated tablets.
Tolzurin, 2 mg, prolonged-release hard capsules are available in the following pack sizes:
PVC/PE/PVDC/Aluminum blisters containing: 28, 56, 84 prolonged-release hard capsules.
Tolzurin, 4 mg, prolonged-release hard capsules are available in the following pack sizes:
PVC/PE/PVDC/Aluminum blisters containing: 28, 56, 84, 98 prolonged-release hard capsules.
Not all pack sizes may be marketed.
Marketing authorization holder
Recordati Polska sp. z o.o.
al. Armii Ludowej 26
00-609 Warsaw
Manufacturer/Importer
Pharmathen S.A.
6, Dervenakion St., 15351 Pallini, Attiki, Greece
Pharmathen International S.A.
Industrial Park Sapes
Rodopi Prefecture, Block 5, 69300 Rodopi, Greece
United Kingdom
Neditol XL 2 mg, 4 mg prolonged-release capsules
(Northern Ireland)
Cyprus
Tolterana 2 mg, 4 mg prolonged-release capsules
Germany
Tolterodin PUREN 4 mg Hartkapseln, retardiert
Spain
Tolterodina Neo Edigen 4 mg cápsulas duras de liberación prolongada EFG
Poland
Tolzurin
Greece
Toldesor 2 mg, 4 mg prolonged-release capsules
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.